Navigation Links
Future diabetes drugs may target new protein interaction

In the March 3 issue of Nature, Johns Hopkins researchers report that two proteins best known for very different activities actually come together to turn the liver into a sugar-producing factory when food is scarce. Because the liver's production of sugar is a damaging problem in people with diabetes, the proteins' interaction might be a target for future drugs to fight the disease, the researchers say.

Under normal circumstances, the liver's production of sugar is a back-up plan that enables survival during food shortages; the brain and certain other critical organs rely on sugar -- specifically glucose -- for the energy to function. In people with diabetes, however, the liver doesn't sense the incoming calories, and it keeps making glucose when it shouldn't.

The researchers discovered that, in fasting mice, the liver's production of sugar kicked into high gear because amounts and activities of the two proteins, called sirtuin1 and PGC1-alpha, increased when dietary calories weren't available. Once mice were fed, levels of the two proteins went down and sugar production ceased.

"It isn't a coincidence," says Pere Puigserver, Ph.D., an assistant professor of cell biology at the Johns Hopkins University School of Medicine's Institute for Basic Biomedical Sciences. "The two proteins actually bind to each other, and without sirtuin1, PGC1 can't make glucose."

A current diabetes-fighting drug, metformin, blocks steps in the glucose-making process, but the new research identifies a critical regulatory step the researchers say could be targeted as well.

PGC1, which Puigserver isolated and cloned in 1998 as a postdoctoral fellow at Harvard, controls gene expression in the liver and other tissues. In the liver, it triggers the conversion of fats into sugar, particularly when access to food is limited. But no one knew exactly how it was controlled or what else it might need in order to launch the sugar-making process.

Sirtuin1,
'"/>

Source:Johns Hopkins Medical Institutions


Page: 1 2 3

Related biology news :

1. Chemists identify key gene in development of type 1 diabetes
2. Rare surgery performed to remove pancreas, prevent diabetes
3. Malfunctioning bone marrow cells sabotage nerve cells in diabetes
4. New imaging technology shown to detect pancreatic inflammation in type 1 diabetes
5. UCSD study clarifies insulins role in blocking release of energy in patients with type II diabetes
6. Researchers reverse juvenile diabetes in animal model
7. Infused spleen cells found not to impact islet recovery and reversal of type 1 diabetes in mice
8. Traditional Chinese medicine for diabetes has scientific backing
9. One-third of adults with diabetes still dont know they have it
10. The molecular mechanism of a diabetes vaccine revealed
11. Compound in dairy products targets diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Future diabetes drugs may target new protein interaction

(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... Rensselaer Polytechnic Institute announced today a $480,000 gift ... the James P. Ferris Fellowship in Astrobiology, which will ... research in the interdisciplinary field of astrobiology. The fellowship ... of chemistry and chemical biology, currently a senior research ...
... a fully functional body: as embryos develop and grow, they ... size of the embryo. The exact mechanism underlying this fundamental ... researchers from EMBL Heidelberg is now one step closer to ... vertebrae in a mouse embryo is controlled by how the ...
... androgen deprivation therapies to prevent precancerous prostate abnormalities developing ... men with precancers with specific genetic alterations, according to ... Cancer Discovery , a journal of the American Association ... of prostate cancer cells are very dependent on signals ...
Cached Biology News:Rensselaer awarded gift to establish fellowship in astrobiology 2Sync to grow 2Preventing prostate cancer through androgen deprivation may have harmful effects 2
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
(Date:8/27/2015)... ... ... Capital Edge Consulting , a nationwide consulting firm that specializes in helping ... one of the top 5000 companies listed on the 2015 Inc. 5000 , ... is truly an honor to be recognized as one of America’s fastest growing companies. ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... conferences in the month of September.  ... present at Rodman & Renshaw,s 17th Annual Global Investment ... PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Group (USA) Reports Second Quarter and Six-Month Results -- NEW YORK, Aug. 19 /PRNewswire-Asia/ -- ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... SAN FRANCISCO, Aug. 19 Jennerex, Inc., a ... commercialization of first-in-class, breakthrough targeted oncolytic products for ... subscribed private placement financing with aggregate gross proceeds ... from this transaction will be used to advance ...
... offers a new transfection kit ideal for biotherapeutic protein ... new Trans IT-PRO™ Kit will decrease time to ... transient transfection. Trans IT-PRO™ Kit uses animal origin ... in suspension CHO and 293 derived cells. Since it ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million 2
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
Request Info...
Biology Products: